Key result
Direct-acting oral anticoagulants lack quality data regarding their safety and efficacy in patients awaiting or having received a solid organ transplant.
Why the study?
There is a dearth of quality data regarding the safety and efficacy of direct-acting oral anticoagulants in patients awaiting organ transplant and those who received a solid organ transplant.
Does direct-acting oral anticoagulants improve safety and efficacy in solid organ transplant recipients?
Does direct-acting oral anticoagulants improve safety and efficacy in solid organ transplant recipients?
Answers are grounded in this paper and cite their sources.
This review highlights the current literature and considerations for DOAC use in the preoperative, perioperative, and postoperative management of solid organ transplant recipients.
Direct-acting oral anticoagulant (DOAC) use has increased dramatically since their introduction because of the growing evidence of proven efficacy and enhanced safety compared with warfarin and the low-molecular-weight heparins in the general population. Unfortunately, there is a dearth of quality data regarding the safety and efficacy of the DOACs in patients awaiting organ transplant and those who received a solid organ transplant. This review aims to evaluate the available literature and considerations regarding anticoagulation use in transplant recipients, focusing on preoperative, perioperative, and postoperative DOAC use.
No takes yet. Share an insight, caveat, or question.
Rimsans et al. (2022) conducted a review in Solid Organ Transplantation. Direct-acting oral anticoagulants (DOACs) vs. Warfarin and low-molecular-weight heparins was evaluated. Direct-acting oral anticoagulants lack quality data regarding their safety and efficacy in patients awaiting or having received a solid organ transplant.
Synapse has enriched 10 related papers. Consider them for comparative context: